Despite widespread early detection and aggressive treatment for prostate cancer in the United States, the use of androgen deprivation therapy (ADT) has been increasing, researchers reported in BJU International (2006;98:973-978).


A study of Medicare beneficiaries showed that ADT prevalence rose from 1.8% in 1993 to 2.9% in 2000. Regions with higher rates of prostate biopsy in 1987-1991 had a higher prevalence of ADT in 1993, 1995, and 1997 Regions with higher rates of radical prostatectomy in 1987-1991 had higher rates of ADT in 1993-1999.

Continue Reading